Pharmacologic treatment of major depression for elderly patients in residential care settings.
A significant drug-placebo difference was found in a double-blind, placebo-controlled study of nortriptyline for treatment of major depression among frail elderly patients living in an institutional setting. This finding confirms the validity of the DSM-III-R diagnosis of major depression and establishes the need for specific psychiatric services for the chronically ill elderly living in nursing homes and congregate housing facilities. The incidence of adverse events requiring early termination of treatment was 34%, demonstrating the vulnerability of these patients and their need for careful monitoring during treatment. High levels of self-care disability and low levels of serum albumin were both associated with decreased therapeutic responses, demonstrating the need for further research on psychopathology in these settings.
Department of Psychiatry, Medical College of Pennsylvania, Philadelphia 19129.
I R
IR
Katz
G M
GM
Simpson
S M
SM
Curlik
P A
PA
Parmelee
C
C
Muhly
D000367:Age Factors; D000368:Aged; D002986:Clinical Trials as Topic; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D004311:Double-Blind Method; D006707:Homes for the Aged; D006801:Humans; D009661:Nortriptyline / Q000009:adverse effects / Q000627:therapeutic use*; D009735:Nursing Homes; D010919:Placebos; D011569:Psychiatric Status Rating Scales; D012112:Residential Facilities
D010919:Placebos; D009661:Nortriptyline